Jeff Sharman, MD, explores how targeted therapies have transformed CLL treatment and what emerging approaches could shape the future of care.
|Videos|May 8, 2020
Expanding Options for Treatment of CLL Using BTK Inhibitors
Author(s)Targeted Oncology
Jennifer R. Brown, MD, PhD, and Alan Skarbnik, MD, describe the rationale for treating chronic lymphocytic leukemia with BTK inhibition, and explore current trends in data that impact treatment selection.
Advertisement
Advertisement
Related to this article
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Anito-Cel Delivers Durable Responses With Low Neurotoxicity in RRMM
2
Risk, Histology, and Metastatic Site Guide First-Line RCC Treatment Choices
3
Elinzanetant Gets Priority Review for VMS From Breast Cancer Endocrine Therapy
4
FDA Application Withdrawn for I-DXd in Small Cell Lung Cancer
5